Aspen Pharmacare annual normalised earnings rise 22% on Mounjaro demand
Aspen Pharmacare (APN) reported annual normalised earnings up 22%, citing strong demand for obesity and diabetes treatment Mounjaro it distributes and improving profitability in its manufacturing business.
By Nqobile DludlaSouth Africa's Aspen Pharmacare JSE:APN reported a 22% rise in annual normalised earnings on Wednesday, helped by strong demand for obesity and diabetes treatment Mounjaro, which it distributes, and improving profitability in its manufacturing business.The drugmaker said normalised…